New Delhi: GlaxoSmithKline Consumer Healthcare on Tuesday said the multi-billion dollar global deal between parent GlaxoSmithKline Plc and Swiss drug major Novartis won't affect its business in India.

The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with USD 10 billion in annual sales. GSK will hold a 63.5 percent stake in the venture.

"This consumer healthcare joint venture will exclude GlaxoSmithKline Consumer Healthcare Ltd India, where GSK plc will continue to hold directly its interests in the listed entity," GlaxoSmithKline Consumer Healthcare (GSKCH) said in a filing to the BSE.

As part of the three-way transaction announced on Tuesday, the Swiss firm will buy GSK's cancer drugs portfolio for USD 16 billion and sell its vaccines business in return for USD 7.1 billion.

Novartis, based in Basel, will acquire GSK's oncology products for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone. Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.

Novartis will divest its vaccines business, excluding flu, for USD 7.1 billion plus royalties. The upfront payment is USD 5.25 billion and up to USD 1.8 billion is in milestones.

Earlier this year, GSK increased its stake in the Indian arm, GlaxoSmithKline Consumer Healthcare, to 75 percent following the completion of a Rs 6,400 crore open offer.

GlaxoSmithKline Consumer Healthcare shares closed at Rs 4,368 on the BSE, up 0.06 percent.

Asked about the impact of the deal on the Indian operations of Novartis, a company spokesperson said: "All of these deals still need regulatory approvals so it is early to say what it means at a country level."

Novartis has announced a portfolio transformation, which enables the company to focus on its leading businesses, building innovation power and global scale in pharmaceuticals, the spokesperson added.